News
AbbVie’s Skyrizi hits the spot in refractory psoriasis
New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, inc
